Respiratory pathogens and associated host–pathogen interfaces

Respiratory pathogens and associated host–pathogen interfaces encompass the diverse array of molecular and cellular interactions between infectious agents—such as viruses (e.g., SARS-CoV-2, Influenza) and bacteria (e.g., Streptococcus pneumoniae)—and the human respiratory tract. These interfaces are defined by specific binding events, such as the interaction between viral glycoproteins and host cell receptors like Angiotensin-converting enzyme 2 (ACE2) or sialic acids, which facilitate pathogen entry and colonization (Hoffmann et al., 2020, Cell; Long et al., 2019, Nature Reviews Microbiology). The host response at these interfaces involves complex signaling pathways, including the activation of Toll-like receptors (TLRs) and the subsequent release of pro-inflammatory cytokines (Kawai & Akira, 2010, Nature Immunology). Therapeutic strategies targeting these interfaces range from vaccines that prime the immune system to monoclonal antibodies and small molecules that block attachment or replication. Because this term refers to a broad category of interactions across multiple species rather than a single protein or pathway, it is considered a research framework rather than a discrete therapeutic target. Understanding these interfaces is vital for addressing respiratory diseases, which remain a leading cause of global morbidity and mortality (GBD 2017 Causes of Death Collaborators, 2018, Lancet).

Other names

Respiratory host-pathogen interactionsRespiratory infection interfacesPathogen-host crosstalk in the lungRespiratory tract infection mechanisms

Drugs targeting these interfaces typically work by blocking pathogen attachment to host cells (e.g., Palivizumab), inhibiting viral or bacterial replication (e.g., Remdesivir, Amoxicillin), or modulating the host's inflammatory response to prevent tissue damage (e.g., Tocilizumab) (Beigel et al., 2020, NEJM; McLellan et al., 2013, Science).